ArticleBMC medical ethics2018
Advance directives as a tool to respect patients' values and preferences: discussion on the case of Alzheimer's disease.
Article in BMC medical ethics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 46 citations in OpenAlex.
- Structuring healthcare advance directives: Evidence from Chinese end-of-life cancer patients' treatment preferences.Health expectations : an international journal of public participation in health care and health policy · 2023Trial
- Advance Research Directives and Supported Consent in Dementia Research.Journal of bioethical inquiry · 2026Article
- Shared care planning in people with cognitive disorders and dementia: a survey among patients and caregivers in Italy.BMC medical ethics · 2024Article
- New Community and Sociohealth Challenges Arising from the Early Diagnosis of Mild Cognitive Impairment (MCI).Journal of personalized medicine · 2023Review
- Italian law n. 219/2017 on consent and advance directives: survey among Ethics Committees on their involvement and possible role.BMC medical ethics · 2022Article
- High-throughput screening for amyloid-Acta pharmaceutica Sinica. B · 2022Article
- Rethinking the Precedent Autonomy, Current Minimal Autonomy, and Current Well-Being in Medical Decisions for Persons with Dementia.Journal of bioethical inquiry · 2022Article
- Advance care planning and advance directives: an overview of the main critical issues.Aging clinical and experimental research · 2022Review
- Exploring the Motivations for Completing Advance Care Directives: A Qualitative Study of Majority/Minority Israeli People Without Dementia.Frontiers in psychiatry · 2022Article
- Practices and perspectives of primary care physicians in Japan and the United States about diagnosing dementia: a qualitative study.BMC geriatrics · 2021Article
- 'I am your son, mother': severe dementia and duties to visit parents who can't recognise you.Medicine, health care, and philosophy · 2020Article
- Unmet needs in community-living persons with dementia are common, often non-medical and related to patient and caregiver characteristics.International psychogeriatrics · 2019Article
- Tube Feeding in Individuals with Advanced Dementia: A Review of Its Burdens and Perceived Benefits.Journal of aging research · 2019Review
- Ethical Issues in the Treatment of Late-Stage Alzheimer's Disease.Journal of Alzheimer's disease : JAD · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe proposal of the new criteria for the diagnosis of Alzheimer's disease (AD) based on biomarker data is making possible a diagnosis of AD at the mild cognitive impairment (MCI) or predementia/prodromal- stage. Given the present lack of effective treatments for AD, the opportunity for the individuals to personally take relevant decisions and plan for their future before and if cognitive deterioration occurs is one the main advantages of an early diagnosis. MAIN BODY: Advance directives are largely seen as an effective tool for planning medical care in the event the subject becomes incompetent. Nevertheless, their value has been questioned with regard to people with dementia by scholars who refer to the arguments of personal identity and of patient's changing interests before and after the onset of dementia. In this paper, I discuss the value of advance directives in Alzheimer's disease and other kind of dementia. Despite critics, I argue that advance directives are especially advisable in dementia and provide reasons in favor of their promotion at an early stage of the disease as a valuable tool to respect patients' values and preferences on medical treatment, including participation in research and end of life decisions. I mainly support advance directives that include both decisions regarding health care and the appointment of an attorney in fact.
conclusionI conclude that patients with AD at a prodromal or early stage should be offered the opportunity to execute an advance directive, and that not to honor a demented individual's directive would be an unacceptable form of discrimination towards those patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.